Rain oncology stock.

May 22, 2023 · Shares of Rain Oncology ( RAIN 0.96%) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated ... Events. News & press releases. Investors. Overview. Stock Information. Analyst Coverage. Stock Quote & Chart. Historical Price Lookup. Investment Calculator.Nov 22, 2023 · The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California. NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to ...Web

At Olema Oncology, we leverage our deep understanding of endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance with the goal of transforming the standard of care for women living with cancer by focusing on developing more convenient and effective therapies. Join us as we aim to design therapies for improving lives.

12 brokers have issued 12-month price objectives for Rain Oncology's stock. Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate …

Rain Oncology Inc. (RAIN) Stock Price | Stock Quote Nasdaq - MarketScreener RAIN ONCOLOGY INC. Rain Oncology Inc. Stock price Equities …The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.We would like to show you a description here but the site won’t allow us.NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will …WebFounded by William J. O’Neil, Investor’s Business Daily provides exclusive stock lists, market data and research, helping investors take advantage of the CAN SLIM system to make more money in ...

9 Mar 2023 ... shares of the Company's convertible preferred stock converted into 7,341,860 shares of Common Stock. ... assets or voting stock of Rain Oncology ...

May 12, 2023 · Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28.

1. Introduction. Driven by many advances in nanomedicine, over the last few decades, there has been significant growth in the research and development of drug delivery devices in the form of polymeric nanoparticles, liposomes, and micelles. (1) The success of these nanocarriers largely depends on the choice of appropriate design parameters to ...Success is Achieved Together. Biosimulation can reduce the size of and cost of human trials, the most expensive and time-consuming part of drug development. In some cases, we can eliminate certain human trials completely. More than 2,000 customers worldwide choose us as their partner for biosimulation software and technology-driven services.3 analysts have issued 1 year price objectives for Surface Oncology's stock. Their SURF share price targets range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 320.6% from the stock's current price. View analysts price targets for SURF or view …Details · Stock Symbol NASDAQ:RAIN · Company Type For Profit.RAIN ONCOLOGY INC RAIN, 2023-11-28 15:15:03 UTC, -0.8998, 6.2198, 1500000. RAIN ... Stock Lookup. Enter stock name: use * for wildcard.Mar 9, 2023 · Non-cash stock-based compensation expense included in G&A expenses were approximately $0.3 million and $1.1 million for the three months and year ended December 31, 2022, respectively, as compared ...

Quantum-Si cuts 12% of workers. Quantum-Si, a proteomics firm, said it would lay off roughly 12% of its workforce in the first quarter of 2023. The restructuring efforts will cost the company roughly $1 million. Since its 2021 merger with a special purpose acquisition company, Quantum-Si’s stock has struggled.Get the latest Oncology Pharma Inc (ONPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Dec 29, 2022 · The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology. Stockholder / Stock options: Rain Therapeutics; Advisory / Consultancy: Chair of Scientific Advisory. Board for Rain Therapeutics; Honoraria (self): Guardant ...Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.The offer is just the latest example of Concentra hoping to snap up a troubled biotech this year, after a reach out to Rain Oncology last month. Tang has already scored success when Concentra used ...

Company Overview. Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than ...

Check out other analyst stock ratings. H.C. Wainwright On Rain Oncology. Analyst Mitchell Kapoor downgraded the rating on the stock to Neutral. “Since LPS harbors the highest prevalence of MDM2 ...Nov 4, 2022 · NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ... Rain Oncology ( NASDAQ: RAIN) fell ~81% in the pre-market Monday after announcing that its lead product candidate, milademetan, did not reach the primary endpoint in a Phase 3 trial for patients ...TSLA Stock 12 Months Forecast. $248.93. (11.27% Upside) Based on 34 Wall Street analysts offering 12 month price targets for Tesla in the last 3 months. The average price target is $248.93 with a high forecast of $380.00 and a low forecast of $85.00. The average price target represents a 11.27% change from the last price of $223.71.Which Rain Oncology insiders have been selling company stock? The following insider sold RAIN shares in the last 24 months: Boxer Capital, Llc ($1,243,750.00). How much insider selling is happening at Rain Oncology?Get a real-time Rain Therapeutics Inc. (RAIN) stock price quote with breaking news, financials, statistics, charts and more. Get a real-time Rain Therapeutics Inc. (RAIN) stock price quote with breaking news, financials, statistics, charts and more. ... About RAIN. Rain Oncology Inc., a late-stage precision oncology company, engages in …WebGet the latest Rain Oncology Inc (RAIN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Coming off stock drops following safety concerns over its recently approved eye injection Syfovre--which turned out to be related to the needle used to deliver the medicine, ... Rain Oncology is laying off 65% of its staff, including its chief medical officer. This news came one week after the company's lead candidate, ...

Find the latest Yext, Inc. (YEXT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Get a real-time Rain Therapeutics Inc. (RAIN) stock price quote with breaking news, financials, statistics, charts and more. Get a real-time Rain Therapeutics Inc. (RAIN) stock price quote with breaking news, financials, statistics, charts and more. ... About RAIN. Rain Oncology Inc., a late-stage precision oncology company, engages in …Web

What is the target price for Rain Oncology (RAIN) stock? The latest price target for Rain Oncology ( NASDAQ: RAIN) was reported by Citigroup on Monday, September 18, 2023. The analyst firm set a ... NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...Rain Oncology Inc (RAIN) stock is trading at $8.41 as of 1:40 PM on Tuesday, Mar 21, a rise of $0.64, or 8.24% from the previous closing price of $7.77. The stock has traded between $7.75 and $8.48 so far today. Volume today is low. So far 87,184 shares have traded compared to average volume of 293,376 shares.Rain Oncology last announced its earnings data on November 9th, 2023. The reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. Rain Oncology has generated ($2.06) earnings per share over the last year (($2.06) diluted earnings per share).Stock Symbol: RAIN . 43 articles about Rain Oncology. Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update. 8/10/2023. Rain Oncology Inc., reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. ... Rain Oncology Inc., a clinical stage company developing precision …Web30 May 2023 ... Related Content · East Bay cancer drug maker's stock plummets on trial results · These companies have no drugs yet, but they're still selling hope.Aug 10, 2023. NEWARK, Calif., August 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. “Rain has been aggressively pursuing a multitude of opportunities as we seek to leverage our clinical execution capabilities and strong cash position to add value to our ...31 May 2023 ... Rain plans to continue evaluating the Phase 3 MANTRA data and present those findings at a medical conference later in the year. The company also ...

Rain Oncology last announced its earnings data on November 9th, 2023. The reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. Rain Oncology has generated ($2.06) earnings per share over the last year (($2.06) diluted earnings per share).May 22, 2023 · Rain Oncology (NASDAQ: RAIN) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company’s ... Shares of precision oncology upstart Rain Oncology (NASDAQ:RAIN) have fallen by nearly 40% since its IPO was priced at $17 in 2021. Trailing twelve month gain is a more respectable +35%. Trailing ...Instagram:https://instagram. best online store to buy goldbest quad insuranceabr reitotcmkts stab 4 Wall Street analysts have issued 1 year target prices for Pyxis Oncology's stock. Their PYXS share price targets range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 629.2% from the stock's current price. hive sharebest penny stocks this week Oct 16, 2023. NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the …WebOct 16, 2023. NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net ... paper trading platform free Rain Oncology Inc (RAIN) stock is down -87.44% while the S&P 500 has risen 0.1% as of 11:09 AM on Monday, May 22. RAIN is down -$8.68 from the previous closing price of $9.93 on volume of 16,197,454 shares. Over the past year the S&P 500 is higher by 5.60% while RAIN is down -51.92%. RAIN lost -$2.61 per share in the over the last 12 months.1. Introduction. Driven by many advances in nanomedicine, over the last few decades, there has been significant growth in the research and development of drug delivery devices in the form of polymeric nanoparticles, liposomes, and micelles. (1) The success of these nanocarriers largely depends on the choice of appropriate design parameters to ...Rainfall totals consider the yearly number of inches of precipitation and the number of days that it rains. Some cities get steady rain over many days while others have torrential downpours that don’t last long. Yearly averages change but s...